Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Expression of CD2, CD25 and/or CD30 in extracutaneous mast cells (MC) is a minor diagnostic criterion for systemic mastocytosis (SM) in the classification of the World Health Organization and International Consensus Classification. So far, it remains unknown whether expression of these antigens on MC is of prognostic significance in SM. We performed a retrospective multi-center study of patients with SM using the data set of the registry of the European Competence Network on Mastocytosis, including 5034 patients with various MC disorders. The percentage of CD2, CD25 and/or CD30 MC was considerably lower in patients with indolent SM compared to patients with advanced SM, including aggressive SM and MC leukemia. Whereas CD25 and CD30 expression in MC could not be associated with prognosis, we found that lack of CD2 expression in MC is associated with a significantly reduced overall survival (OS) in patients with SM (p < 0.0001). Lack of CD2 was also associated with the presence of extramedullary involvement affecting the spleen, liver, and/or lymph nodes (odds ratio 2.63 compared to SM with CD2 MC). Together, lack of CD2 expression in MC is a prognostic marker and indicator of reduced OS and extramedullary disease expansion in patients with SM.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879856 | PMC |
| http://dx.doi.org/10.1038/s41375-024-02504-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world characteristics of systemic mastocytosis in Romania: insights from a reference-center-based descriptive study.
J Med Life
July 2025
Department of Dermatology and Allergology, Elias Emergency University Hospital, Bucharest, Romania.
Systemic mastocytosis (SM) is a rare clonal mast cell disease characterized by heterogeneous clinical presentations and molecular features that vary across different regions; however, data from Central-Eastern Europe remain limited. This study aimed to describe the demographic, clinical, laboratory, and molecular characteristics of Romanian adults diagnosed with SM and followed at the national reference center for mast cell disorders in Bucharest, while also exploring real-world management patterns and outcomes. We conducted a retrospective observational study including 162 adult patients evaluated between January 2006 and March 2025 who met the 2022 World Health Organization criteria for SM.
View Article and Find Full Text PDFWell-differentiated systemic mastocytosis: genetics, mast cell immunophenotypes, and KIT autophosphorylation.
J Allergy Clin Immunol
August 2025
Allergy, Immunology, & Immunizations Service, Walter Reed National Military Medical Center, Bethesda, MD; Department of Medicine, Uniformed Services University, Bethesda, MD. Electronic address:
Background: Well-differentiated systemic mastocytosis (WDSM) is a rare myeloid neoplasm where the genetic etiology is often unknown.
Objective: We aimed to assess WDSM patients for novel KIT variants, mast cell (MC) aberrant immunophenotypes, and KIT autophosphorylation patterns.
Methods: Next-generation sequencing (NGS), MC immunophenotyping, and KIT autophosphorylation studies were performed.
Case report: Experience of a rare case of primary acute mast cell leukemia.
Leuk Res Rep
April 2025
Department of Hematology, Peking University First Hospital Taiyuan Branch (Taiyuan Central Hospital of Shanxi Medical University), No. 256, Fendong Street, Xiaodian District, Taiyuan, Shanxi 030009, PR China.
Backgrounds: Mast cell leukemia (MCL) is a rare and aggressive form of systemic mastocytosis with a poor prognosis. Understanding the different therapeutic responses to corticosteroids in MCL is crucial for improving patient outcomes.
Case Presentation: We present a case of a 74-year-old Chinese female with primary acute MCL who exhibited different responses to dexamethasone and methylprednisolone.
Critical Pitfalls in the Flow Cytometric Analysis of Mast Cells in Patients With Systemic Mastocytosis.
Cytometry A
August 2025
Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Systemic mastocytosis (SM) is a neoplastic disease characterized by abnormal mast cell (MC) activation and proliferation. Accurate diagnosis often relies on flow cytometry to detect aberrant CD25, CD2, and CD30 expression on MCs in bone marrow (BM). However, the frequently low abundance of MCs in BM, lack of completely specific antigens, and strong and highly variable autofluorescence can cause misinterpretation and lead to diagnostic misclassifications.
View Article and Find Full Text PDFComposite mantle cell lymphoma and T-cell prolymphocytic leukemia: a case report.
J Clin Exp Hematop
June 2025
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan.
We encountered a patient with composite mantle cell lymphoma (MCL) and T-cell prolymphocytic leukemia (T-PLL) who presented with inactive disease to active T-PLL over 8 years. A 71-year-old man was diagnosed with MCL with an atypical T-cell population showing CD2+, CD3-, CD4+, CD7+, CD8-, and CD25+; however, the cause of the T-cell population could not be determined at the first MCL diagnosis. When MCL relapsed approximately 8 years after the initial treatment, T-PLL was definitively diagnosed using the T-PLL International Study Group criteria.
View Article and Find Full Text PDF